Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Aztreonam for Cystic Fibrosis Nasal Disease
NCT02730793Phase 2Terminated
- Sponsor
- Virginia Commonwealth University
- Start
- Jan 2017
- Primary completion
- Sep 2019
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aztreonam in cystic fibrosis (CF) (2 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Number of Protocol-defined Pulmonary Exacerbations Treated With IV Anti-pseudomonal Antibiotics at Day 140. Started Jan 2017; status: terminated.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02730793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730793.